Andrew Klauk’s Post

The journey from scientific discovery to commercial success in cell and gene therapy is full of challenges. These challenges were the focus of a recent panel at the #PharmaLifeSciences2024: Advancements in Cell and Gene Therapy virtual summit, featuring Likarda CEO, Dr. Stella K. Vnook. Key topics included scaling production, patient engagement, and navigating regulatory hurdles—along with strategies to overcome them. Thank you to TechTarget for summarizing this insightful discussion, which you can read here: https://lnkd.in/gpreEJes #CellTherapy #GeneTherapy #HealthcareInnovation #Biotech

Are sound waves the key to revolutionizing gene therapy? In this groundbreaking episode, we sit down with Gabriel Dumy, CTO and Co-founder at Kolibri, a company revolutionizing the way we grow and engineer cells at scale using acoustic waves. Gabriel discusses the challenges facing modern bioproduction and unveils an exciting solution that is setting the stage for the future of gene therapy.

In an industry where change is ever constant, Andelyn Biosciences stands as your steadfast partner in gene therapy manufacturing. With over two decades of experience and expertise, our commitment to growth and innovation ensures we're here for you, ready to bring your groundbreaking therapies from the lab to the patient. See what a feasibility study and yield assessment can do to get your program started on a path to process industrialization: https://buff.ly/3UzqzNP #andelynbiosciences

The EOS Intelligence #LifeSciences team's April topic is CGT. If this is a topic that interests you, look out for #eosperspectives from Stuart Wagner, MBA & Bhabesh Panigrahi #cellandgenetherapy #eosintelligence

Discover how decentralized manufacturing is reshaping the landscape of cell and gene therapy development in this blog capturing insights from our Bridging the Gap webinar series. Gain valuable insights from experts like Dorothea Ledergerber, PhD, Chief Technical Officer at Tigen Pharma, and Patrick Hanley, PhD, Director of the Cellular Therapy Program at Children’s National Hospital. Read the full blog and register for future webinars here: https://hubs.ly/Q02xHWy70 #CellTherapy #GeneTherapy #Innovation #WebinarSeries

Rapid growth in cell and gene therapy (CGT) is leading scientists to consider how patient-centered treatments can be delivered uninterruptedly through a time-dependent and agile approach. Read our new BioPhorum publication by Maria Rende, PhD, MBioSci, Cell and Gene Therapy Expert, to learn the requirements of different CGT outbound supply chains. https://sar.to/jgy34 #SimplifyingProgress #InThisTogether #CellandGeneTherapy #AdvancedTherapies #CellTherapy #GeneTherapy

Consider this 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 that will drive the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀. My presentation will focus on setting apart your therapy for payers through science. My panel will discuss strategies for cross-functional collaboration. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲 – https://ter.li/lhvjuu

If you are not watching it right now, register and access the recordings later, this is definitely worth listening to. Fascinating topics. Valuable insights and business-minded outlook. Each session highlights the current landscape, gets right to the heart of the existing issues and identifies the most promising ways forward.

Conclusions, take home messages from the fantastic business panel with Jack O'Meara, Kathryn Golden, Lee Dunham, Michael Anstey at Innovation Forum's Healthcare 2.0 Cell and Gene Therapy conference yesterday: 1. 'The Maths doesn't work' - Michael Anstey brought the high level message home: for VCs to invest, there must be good ROI balanced by risk. In rare disease the addressable market size is small, while the RnD costs are high...How can we make the Maths work? ➗ are rare disease RnD and n=1 trials forever stuck within academia and philantropy? 2. Cost vs Price - RnD attrition + high manufacturing costs hike the price up. Jack O'Meara brought up a new pricing model for 'once and done' cures: a success-based price structure with an affordable upfront payment followed by a lifetime direct debit setup. At first this sounds just ethically wrong ('rent' your life until the day you die?!), but if we think of the price of Zolgensma making it inaccessible for children whose life prospects it significantly improves, that puts this into perspective. Would this ever work within the NHS though? 🤔 3. Automation first - Kathryn Golden raised the point that using automation during RnD phase then scaling it to manufacture establishes the mindset within the company from the get go → removes the bottleneck of having to redevelop manual processes into automated ones. BUT, there is always a but - how could an early stage biotech possibly afford this? This is where Cell and Gene Therapy Catapult can come in providing a test bed - a well set conclusion from Lee Dunham ✨ Arctoris is here to apply modular automation during the RnD on a project cost basis. The day has come where automation is not only affordable in the HTS and manufacturing context, we can use it affordably in low / mid throughput setting. Come and talk to us if you'd like to give it a go → better data will lead to better decisions and as Bradley Hardiman has so eloquently put it, VC's would lose their shirts less often, and spend less time trying to climb out of a ditch 💵

💥Are you attending #ASGCT and are eager to revolutionize your AAV analysis? Swing by Booth 2228 and visit my colleague Andrew Newton to discuss how the #LabChip GXII Touch can help 'Revv' up your AAV development! 🔬 The LabChip GXII Touch system can make #AAV characterization easier. Our system streamlines your AAV characterization, saving you time and effort. The integrated approach minimizes errors and technical glitches, leading to more reliable results. You can analyze up to 96 samples per run with rapid, microfluidic capillary electrophoresis. ⏱ Get a complete picture of your AAV capsids in minutes: • Partials estimation • Purity assessment of viral proteins • Genomic integrity of genomic insert (#ssDNA) • Purity of genomic insert • Sizing of genomic insert • AAV empty full analysis data • Expected viral protein egrams Come by and see how this system can help you! #revvity #WeAreRevvity #UnitedinImpact #UnitedinScience #InnovationUnleashed #LabchipGXIITouch #microfluidics #microfluidic #capillaryelectrophoresis #highthroughput #lifescience #biotech #biotechnology #biopharma #biopharmaceuticals #protein #nucleicacid #cellandgenetherapy #cgt #mRNA #proteomics #genomics #biochemistry #molecularbiology #innovation #labequipment #proteinanalysis #drugdiscovery #drugdevelopment #researchanddevelopment #gmp #aav #lnp